Skip to main content
. Author manuscript; available in PMC: 2010 Jun 11.
Published in final edited form as: Clin Cancer Res. 2005 Dec 15;11(24 Pt 1):8856–8865. doi: 10.1158/1078-0432.CCR-05-1365

Fig. 1.

Fig. 1

Biodistribution of doxorubicin after single and repetitive treatments. A, tissue and tumor biodistribution of doxorubicin after single (day 14) and repetitive (days 7 and 14) i.v. doses of 5.67 mg/kg free doxorubicin. B, tissue and tumor biodistribution of doxorubicin after day 14 (d14) and days 7 and 14 (d7&d14) administration of 5.67 mg/kg SSL-DXR. Columns, mean (n = 4-8 animals); bars, SE. For animals treated on days 7 and 14 with SSL-DXR, a significant decrease in liver deposition was observed at 24 and 48 hours and in spleen deposition at 8, 24, and 48 hours. Naive pooled data analysis showed that repetitive administration of SSL-DXR significantly increased the cumulative brain tumor deposition compared with a single treatment. Temporal and treatment-mediated differences in drug deposition were tested in SAS using a stepwise two-way (time and treatment) ANOVA followed by a post hoc Bonferroni t test. *, P < 0.05.